Stock listing
Nuvation Bio Inc.
Selected listing: NUVB · NYSE · USD · US
Nuvation Bio Inc. (NYSE:NUVB), Health Technology. Latest release Sep 16, 2026: Nuvation Bio Announces FDA Approval of Supplemental New Drug Application…
- Ticker
- NYSE:NUVB
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NYSE
- Currency
- USD
About Nuvation Bio Inc.
Nuvation Bio Inc. is a public company traded under the ticker NUVB in the American market. Nuvation Bio focuses on developing innovative therapies to improve patient outcomes.
Latest news from Nuvation Bio Inc.
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
September 15, 2026
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
September 15, 2026
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
August 20, 2026
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
August 4, 2026